Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,067 total articles
CRISPR Therapeutics ($60.09) looks actionable after a pediatric expansion for Casgevy and renewed analyst optimism. The company is early-commercial with tiny revenue today but a deep cash cushion and several upcoming catalysts. Trade idea: initiate a long at $60.09, stop $48.00, target $90.00 with a mid-term horizon (45 trading days). Expect volati…
Ternium (TX) looks attractively priced at $41.77 with a market cap near $8.43B, P/B ~0.67 and a 5.3% dividend yield. Fundamentals are cyclical but stable: integrated steel and mining operations, improving short interest, and a 52-week range that leaves upside to the $51.73 high. This trade idea lays out an actionable long with an entry at $41.77, s…
Nvidia pulled back into the $190s after a recent run. Fundamentals - $4.78T market cap, 81.7% ROE, $119B free cash flow - still justify a premium. This trade targets a bounce back to the $240 area over the next 45 trading days with a disciplined $170 stop to limit downside.
Hims & Hers ($36.77) is carving out a breakout above multi-week resistance as technical momentum aligns with a strategic pivot: from high-margin GLP-1 compounding toward branded weight-loss distribution, international scale via the Eucalyptus acquisition, and product diversification. This trade buys that the market is beginning to re-rate HIMS as a…
American Electric Power (AEP) is a classic infrastructure beneficiary of the AI data-center boom. With the largest U.S. transmission system, $75.4B market cap, a $78B five-year capital plan and 63 GW of contracted load by 2030, AEP offers steady earnings growth, a 2.7% yield, and near-term momentum. This trade idea buys AEP for long-term upside whi…
Grifois is trading near its 52-week low after a period of operational disruptions and regulatory scrutiny. With a market cap of $6.32B, a P/E of ~10x, PB under 1x, and improving volume trends, the risk/reward now favors taking a tactically sized long position. This trade idea lays out entry, stop, targets, catalysts, and the specific horizon (180 t…
Kymera Therapeutics is a clinical-stage leader in small-molecule targeted protein degradation (TPD). With Phase 1/1b data showing deep target engagement for KT-621, multiple upcoming proof-of-concept readouts through 2027, a $1.6B cash runway into 2029, and a market cap of roughly $9.38B, Kymera looks set for near-term re-rating. This article lays …
SK Hynix's decision to list in the U.S. is more than a secondary share offering - it materially expands the company's investor base, improves price discovery, and creates a structural catalyst for the memory industry. I recommend a long trade for patient investors looking to play a potential re-rating and improved M&A optionality over the next 180 …
KLA's inspection and metrology franchise offers more stable leverage to advanced packaging and AI-driven fab demand than lithography alone. With $4.0B in free cash flow, an 80% ROE and recent guidance tailwinds, KLA presents a tactical long with defined risk controls versus larger, more concentrated peers.
Monopar (MNPR) has closed the informational gap that left investors guessing about ALXN1840's clinical impact. Recent Phase 2 and Phase 3 readouts, an NDA submission on track for mid-2026, and a healthy cash runway tilt the risk-reward toward upside. This trade idea lays out an actionable long: entry at $97.50, stop at $80.00, target $145.00, with …
Lucid Diagnostics (LUCD) trades like a binary healthcare small cap: modest commercial traction, tight liquidity, and heavy short interest. A clearance or favorable Medicare coverage decision for its reflux-to-cancer screening test would likely re-rate the stock; absent that, the company faces cash burn and dilution risk. This trade idea offers a co…
Custom Truck One Source plunged into the $10 area on heavy volume. Fundamentals still show accelerating top-line with Q2 2025 revenue of $511.5M and strengthening infrastructure demand, while valuation metrics (EV/EBITDA ~11.2, P/S ~1.15) leave room for a recovery. This is a tactical swing-long trade: entry $10.03, target $12.00, stop $9.00, horizo…
PTC combines category-leading CAD/PLM products with ThingWorx digital‑twin and IIoT software. At $124.54, the stock trades at roughly 11.5x earnings with healthy ROE and cash flow, offering an asymmetric risk/reward for a position trade over the next 180 trading days.
Meta is trading off its 52-week highs after a heavy-capex buildout. The company has a ~$1.48T market cap, $48.25B in free cash flow last reported, and P/E around 21. If Meta monetizes excess GPU capacity by renting compute, its large CapEx becomes a recurring revenue stream that can compress perceived valuation risk. This trade targets $700 with a …
Archer Aviation has cleared three of four FAA certification phases and sits on a multi-billion-dollar backlog and strategic OEM support. At a $3.8B market cap and an enterprise value of roughly $2.93B, the stock is a speculative long that can re-rate if Phase 4 wraps and pilots/production milestones follow. This trade idea lays out an entry at $4.9…
Primerica (PRI) is trading near year highs but still offers a reasonable valuation backed by high ROE (30.5%), modest leverage (debt/equity ~0.72) and profitable segments beyond core term life. The firm's push into Investment & Savings and Senior Health distribution — plus steady underwriting profits on an in-force book — gives a structural growth …
Planet Labs ($31.38) is a volatile but improving business: daily Earth-observation data, accelerating revenue trends, and positive free cash flow. The market is pricing steep growth expectations (P/S ~33), but a recent sector rotation and pullback create a tactical buying opportunity. Trade Plan: enter at $31.00, stop $27.00, primary target $48.00 …
Upstart looks like a classic growth-recovery trade: strong top-line momentum, improving profitability, and a lower short-term valuation than its 2025 highs. We like the risk/reward here with an entry near $34.80, a $45 target for the rally window and a $30 stop to limit downside if funding or Model 22 litigation issues resurface.
Contango Silver & Gold is transforming from a collection of assets into an operational platform after acquiring Lucky Shot and delivering extremely high-grade drill results. With a market cap near $531m, manageable leverage and heavy recent insider-driven M&A activity, this trade idea takes a constructive stance: buy on constructive technicals and …
Perdoceo Education has delivered meaningful earnings and free cash flow expansion while keeping debt nearly non-existent. At about $34.45 and ~13x earnings, the stock looks like a reasonable value pick with multiple near-term catalysts. We upgrade to a Buy and lay out an actionable swing trade with clear entry, stop and target.
ExxonMobil's combination of durable free cash flow, a ~3% yield, low leverage, and pipeline of growth-led projects (Guyana, Permian, LNG) creates a favorable risk-reward setup near $137. I am upgrading to a buy and re-entering with a measured long-term trade plan: entry $137.00, target $165.00, stop loss $125.00, horizon 180 trading days.
MTY Food Group (MTY) is a franchising-and-acquisition-led restaurant roll-up trading at a valuation below its historical average. With recurring franchise cash flows, a modest net cash position and multiple integration levers to drive margin expansion, MTY looks like a pragmatic mid-term long. This trade idea lays out a clear entry, stop and target…
Rocket Lab's $8 billion Iridium acquisition is a tectonic shift: it pairs a growing launch and spacecraft manufacturer with an established global satellite network. The deal amplifies recurring revenue potential, widens addressable markets (IoT, aviation, maritime, positioning) and accelerates vertical integration. The stock is richly priced today,…
Nuveen New York Quality Municipal Income Fund (NAN) offers an attractive monthly distribution (yield ~7.34%), trading near its 52-week high with bullish technicals. For income-oriented investors who can tolerate CEF volatility and municipal-credit risk, a long trade with a clear stop and target offers a favorable risk/reward over a 180-trading-day …
Kymera is trading with a biotech premium but also with cash and clinical catalysts in H2 2026 that could re-rate the stock. We lay out a long trade plan to capture the KT-579 Phase 1 readout and ongoing KT-621 momentum while managing binary clinical risk.
